Nephron Pharmaceuticals Raises $350M

Nephron Pharmaceuticals

Nephron Pharmaceuticals, a West Columbia, SC-based provider of inhalation solutions and suspension products, raised $350M in funding.

The round was led by BlackRock Capital Investment Advisors, PNC Bank, and National Association.

The company intends to use the funds to support future growth of the pharmaceutical manufacturer.

Led by CEO Lou Kennedy, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates a 503B Outsourcing Facility division, which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America.